Of note, our research exhibited decreases in the levels of MMP-9 and ROS, and these cytokines after U50448H treatment, indicating U50448H as a promising favorable medicine for the treatment of ALI secondary to CPB. This evidence concerns the gene MMP9 and acute respiratory distress syndrome.